AlphaQuest LLC Acquires 48,250 Shares of Avanos Medical, Inc. $AVNS

AlphaQuest LLC increased its holdings in shares of Avanos Medical, Inc. (NYSE:AVNS) by 130.1% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 85,341 shares of the company’s stock after purchasing an additional 48,250 shares during the quarter. AlphaQuest LLC owned 0.18% of Avanos Medical worth $987,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Millennium Management LLC boosted its holdings in shares of Avanos Medical by 508.3% in the first quarter. Millennium Management LLC now owns 547,740 shares of the company’s stock valued at $7,849,000 after buying an additional 457,703 shares during the period. AQR Capital Management LLC lifted its position in Avanos Medical by 190.4% in the 2nd quarter. AQR Capital Management LLC now owns 560,052 shares of the company’s stock valued at $6,855,000 after acquiring an additional 367,188 shares in the last quarter. Acadian Asset Management LLC acquired a new position in Avanos Medical in the 2nd quarter worth $3,212,000. Lazard Asset Management LLC increased its holdings in Avanos Medical by 3,689.1% during the 2nd quarter. Lazard Asset Management LLC now owns 237,615 shares of the company’s stock worth $2,908,000 after purchasing an additional 231,344 shares in the last quarter. Finally, Qube Research & Technologies Ltd raised its stake in shares of Avanos Medical by 32.5% in the 2nd quarter. Qube Research & Technologies Ltd now owns 625,409 shares of the company’s stock valued at $7,655,000 after purchasing an additional 153,547 shares during the period. Institutional investors own 95.17% of the company’s stock.

Insider Buying and Selling

In other news, SVP Kerr Holbrook sold 15,000 shares of Avanos Medical stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $11.00, for a total value of $165,000.00. Following the completion of the transaction, the senior vice president owned 83,860 shares of the company’s stock, valued at $922,460. This trade represents a 15.17% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 2.64% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avanos Medical in a research report on Monday, December 22nd. Zacks Research upgraded Avanos Medical from a “strong sell” rating to a “hold” rating in a research note on Monday, January 26th. Finally, Wall Street Zen raised Avanos Medical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Reduce”.

Avanos Medical Price Performance

NYSE:AVNS opened at $13.45 on Tuesday. Avanos Medical, Inc. has a 52-week low of $9.30 and a 52-week high of $17.54. The company has a market cap of $624.40 million, a P/E ratio of -1.32 and a beta of 1.09. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.36 and a current ratio of 2.38. The stock’s 50-day simple moving average is $11.92 and its 200 day simple moving average is $11.67.

Avanos Medical (NYSE:AVNS) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $0.22 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.10. Avanos Medical had a positive return on equity of 6.21% and a negative net margin of 67.00%.The firm had revenue of $177.80 million during the quarter, compared to the consensus estimate of $164.50 million. During the same period last year, the company earned $0.33 earnings per share. The business’s revenue was up 4.3% compared to the same quarter last year. Avanos Medical has set its FY 2025 guidance at 0.850-0.950 EPS. As a group, sell-side analysts forecast that Avanos Medical, Inc. will post 1.32 EPS for the current fiscal year.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.